Efficacy of topical administration of eprinomectin for treatment of ear mite infestation in six rabbits

Six rabbits naturally infested with Psoroptes cuniculi were treated topically on the skin at the base of the neck with 0.5 mg kg(-1) of 0.5% pour-on eprinomectin for cattle, twice at 14-day intervals. Efficacy of the drug was based on the disappearance of clinical signs and the absence of live mites for a period of 6 weeks. Clinical improvement was seen within 3 days of the first application; however, complete recovery of clinical signs and elimination of mites in 5/6 rabbits did not occur until the end of the study. No adverse reactions attributable to eprinomectin treatment were observed during the observation period. Results of this trial indicated that eprinomectin was partially effective in the treatment of psoroptic mange in rabbits.     

Use of selamectin for the treatment of psoroptic and sarcoptic mite infestation in rabbits

Selamectin, a novel avermectin compound, was evaluated for its efficacy against naturally occurring infestations of Psoroptes cuniculi and Sarcoptes scabiei. A total of 42 New Zealand rabbits with psoroptic mange and 37 Angora rabbits with sarcoptic mange were used in the present study. On day 0, infested rabbits were treated topically with either selamectin at minimum dose of 6 mg kg(-1) (6-18 mg kg(-1) for New Zealand rabbits, n = 31 and 10-12 mg kg(-1) for Angora rabbits, n = 23) or vehicle only (control groups, n = 11 for New Zealand rabbits, n = 14 for Angora rabbits). The efficacy of selamectin was assessed both clinically and parasitologically by the presence or absence of viable mites. Rabbits were scraped for sarcoptic mites on days 7, 14, 28, 42 and 56 and had otoscopeic and/or microscopic examination for the detection of Psoroptes mites on days 7, 14, 42 and 56. Fisher's exact test was used to assess differences between the vehicle and selamectin treatment in the number of rabbits without mites (cure rates) on each assessment date. It was found that significantly fewer selamectin-treated rabbits had mites detected on skin scrapings (for S. scabiei) or otoscopeic and/or microscopic examination (for P. cuniculi) (P < 0.01) than the vehicle group. Results of the present study suggest that selamectin is effective against naturally infestations of P. cuniculi and S. scabiei in rabbits.     

P‐24 Efficacy of selamectin in canine scabies and ear mite infestation in Korea

A randomized and controlled field study was performed in canine patients to evaluate the efficacy of selamectin in the treatment of naturally occurring Sarcoptes scabiei and Otodectes cynotis infestations in dogs. A total of 227 dogs from six veterinary practices in South Korea were included. Dogs were randomly assigned to treatment with selamectin or a positive‐control product. Selamectin was administered as a unit dose providing a minimum of 6 mg/kg in a topical preparation applied to the skin in a single spot on days 0 and 30 [S. scabiei (n = 113) and O. cynotis (n = 114)]. The presence of parasites was assessed before treatment and at 14, 30 and 60 days after the initiation of treatment. The animals were evaluated clinically at each assessment period. Based on skin scrapings, the efficacy of selamectin against S. scabiei infestations on dogs was >95% by day 30, and 100% by day 60. Against O. cynotis, selamectin eliminated mites in 100% of dogs by day 60. However, clinical signs of pruritus, erythema, scale, and crusted papules did not diminish concomittantly with resolution of S. scabiei in skin scrapings. The positive‐control products achieved similar results. Therefore, selamectin was safe and effective against sarcoptic mange and ear mites in dogs. Funding: Pfizer Animal Health.     

Efficacy of selamectin in the treatment of cheyletiellosis in pet rabbits

Cheyletiellosis is a very common parasitic skin disorder of pet rabbits typically associated with pruritus and scaling. In this study, a total 23 rabbits with cheyletiellosis were treated with a single topical application of selamectin at a dose of 12 mg kg(-1). All rabbits were examined at 3 and 5 weeks after treatment. Five weeks after selamectin application, the scaling and pruritus had resolved in all 23 rabbits, and microscopic examination of epidermal debris collected by acetate tape and flea combing was all negative for mites and eggs. No side-effects were observed in any of the rabbits. This indicates that selamectin is an effective treatment for cheyletiellosis in rabbits.     

Efficacy of selamectin in the treatment of nasal mite (Pneumonyssoides caninum) infection in dogs

In a laboratory study to evaluate the efficacy of selamectin for treatment of canine nasal mite infection, 12 purpose-bred beagles were experimentally infected with Pneumonyssoides caninum (P. caninum). Six of the dogs were treated with selamectin applied to the skin of the back at dosages of 6 to 24 mg/kg for three times at 2-week intervals. The remaining six dogs were an untreated control group. At necropsy 39 to 46 days after inoculation, no P. caninum mites were found in any of the treated dogs. In contrast, nasal mites were found in five of the untreated dogs. This difference was statistically significant at P=0.015.     

Pharmacokinetics of selamectin following intravenous,oral and topical administration in cats and dogs

The pharmacokinetics of selamectin were evaluated in cats and dogs, following intravenous (0.05, 0.1 and 0.2 mg/kg), topical (24 mg/kg) and oral (24 mg/kg) administration. Following selamectin administration, serial blood samples were collected and plasma concentrations were determined by high performance liquid chromatography (HPLC). After intravenous administration of selamectin to cats and dogs, the mean maximum plasma concentrations and area under the concentration-time curve (AUC) were linearly related to the dose, and mean systemic clearance (Clb) and steady-state volume of distribution (Vd(ss)) were independent of dose. Plasma concentrations after intravenous administration declined polyexponentially in cats and biphasically in dogs, with mean terminal phase half-lives (t(1/2)) of approximately 69 h in cats and 14 h in dogs. In cats, overall Clb was 0.470 +/- 0.039 mL/min/kg (+/-SD) and overall Vd(ss) was 2.19 +/- 0.05 L/kg, compared with values of 1.18 +/- 0.31 mL/min/kg and 1.24 +/- 0.26 L/kg, respectively, in dogs. After topical administration, the mean C(max) in cats was 5513 +/- 2173 ng/mL reached at a time (T(max)) of 15 +/- 12 h postadministration; in dogs, C(max) was 86.5 +/- 34.0 ng/mL at T(max) of 72 +/- 48 h. Bioavailability was 74% in cats and 4.4% in dogs. Following oral administration to cats, mean C(max) was 11,929 +/- 5922 ng/mL at T(max) of 7 +/- 6 h and bioavailability was 109%. In dogs, mean C(max) was 7630 +/- 3140 ng/mL at T(max) of 8 +/- 5 h and bioavailability was 62%. There were no selamectin-related adverse effects and no sex differences in pharmacokinetic parameters. Linearity was established in cats and dogs for plasma concentrations up to 874 and 636 ng/mL, respectively. Pharmacokinetic evaluations for selamectin following intravenous administration indicated a slower elimination from the central compartment in cats than in dogs. This was reflected in slower clearance and longer t(1/2) in cats, probably as a result of species-related differences in metabolism and excretion. Inter-species differences in pharmacokinetic profiles were also observed following topical administration where differences in transdermal flux rates may have contributed to the overall differences in systemic bioavailability.     

Efficacy of topical eprinomectin in the treatment of Chorioptes sp. infestation in alpacas and llamas

Chorioptes sp. mite infestation is increasingly recognized as a cause of skin disease in New World camelids and there is a need for an effective treatment protocol to eliminate herd infestation. In this field trial, eprinomectin applied topically at the rate of 0.5 mg kg(-1) weekly for 10 weeks was found to be ineffective in a herd of 12 llamas and 16 alpacas.     

Efficacy of an injectable formulation of eprinomectin against Psoroptes cuniculi, the ear mange mite in rabbits

Thirty rabbits naturally infected with ear mange mite, Psoroptes cuniculi, were subcutaneously administrated with a single dose of eprinomectin at 100, 200 and 300 microg/kg body weight or vehicle on day 0. The extent of lesions was scored on day -6 (prior to treatment), day 0 (treated), days 7, 14, 21, 28 and 35, the ear scabs were collected simultaneously; mites in scabs were examined and counted. The results showed that a single dose of eprinomectin at 200 or 300 microg/kg body weight following subcutaneous administration was able to eliminate P. cuniculi infection in rabbits, and a dose of eprinomectin at 100 microg/kg could significantly reduce mites but was unable to eliminate P. cuniculi.     

Use of topical selamectin for the treatment of Syphacia muris infection in laboratory rats

Efficacy of selamectin was studied in naturally acquired S. muris infections in rats. Fourty-eight S. muris-positive rats were divided into six treated and two control groups. Selamectin (6 mg/kg) was applied topically to the skin in a single spot at the base of the neck in the treatment group. The rats of treated and control groups were necropsied on the 24th day after the treatment. Topical selamectin was found to be 40.7-63.3% effective (based on egg per gram method) in eliminating S. muris infection in rats. The efficacy of the treatment against S. muris (based on adult worm counts) in male and female rats was 35.14-58.88%, respectively (mean 48.39%).     

Use of topical selamectin for the treatment of Trichosomoides crassicauda infection in laboratory rats

The present study investigated the efficacy of topical selamectin for elimination of naturally acquired Trichosomoides crassicauda infection in rats. Twelve T. crassicauda-positive rats were assigned to the treatment group and six rats were assigned to the control group. Selamectin (6 mg/kg) was applied topically to the skin in a single spot at the base of the neck in front of the scapulae in the treatment group. To assess the efficacy of the treatment, animal faeces were investigated with the use of the flotation technique on days 0, 4, 14 and 24 after selamectin application. The rats of the treatment and control groups were necropsied on the day 24. In the treatment group, 7 of 12 infected rats were cured completely. Topical selamectin was found to be effective in eliminating T. crassicauda infection in rats.     

Efficacy of a single dose of an otic ivermectin preparation or selamectin for the treatment of Otodectes cynotis infestation in naturally infected cats

Otodectes cynotis infestation is common in kittens housed in crowded environments like animal shelters. It is unknown how rapidly O cynotis is killed within the first 72h of treatment with currently available products. Kittens ≥4 weeks of age with live O cynotis in both ears (AU) were administered 0.5ml of 0.01% ivermectin otic suspension (Acarexx; Idexx Pharmaceuticals) once, AU or selamectin (Revolution; Pfizer Animal Health) once, on the skin following the manufacturer's instructions. Repeat microscopic examination was performed on individual ears based on a randomization schedule during the 72h after treatment. There was no evidence of toxicity with either drug and administration of 0.01% ivermectin significantly reduced the time to live mite-free status compared to selamectin. Both drugs have an effect against O cynotis as early as 10-12h after administration with an increasing effect over time.     

Efficacy of selamectin administered topically in the treatment of feline otoacariosis

The efficacy of a novel avermectin, selamectin (Stronghold, Pfizer), was evaluated against naturally acquired aural infestations of Otodectes cynotis. Selamectin was administered topically in a single spot to the skin of each animal's back at the base of the neck in front of the scapulae at a minimum dosage of 6mgkg(-1). Thirty cats of a cattery of 120 animals with an endemic infestation were treated on days 0 and 30. Including untreated control cats was therefore not possible because of animal welfare consideration. Clinical examination and visualization of mites by otoscopic examination of the external ear canal and microscopic examination of aural debris/exudate were performed twice weekly from days 0 to 30. On day 0 (and day 28 if the ears canals were erythematous), a swab was taken from each canal and sent to bacteriology and mycology units for detection and identification of bacteria (Staphylococcus mainly) and yeast (Malassezia pachydermatis only).Selamectin was safe, parasites were killed before day 3 and eliminated before day 17. Selamectin was 100% effective against natural aural infestations, even if erythema (26-33% of cats) and scratch reflex (23-40% of cats) persisted for 2 weeks after the cats tested negative for mites.     

Efficacy and safety of selamectin against gastrointestinal nematodes in cats presented as veterinary patients

A series of randomized, controlled, masked, field (veterinary patient) studies were conducted in the USA and Europe to evaluate the efficacy of selamectin, a novel macrocyclic lactone of the avermectin subclass, in the treatment of naturally acquired gastrointestinal nematode infections in cats. After confirmation of ascarid and/or hookworm infection, 298 cats of various ages and breeds were randomly assigned to treatment with selamectin (n=202) or an existing commercially approved positive-control product (n=96). Unit doses of selamectin (providing a minimum dosage of 6mgkg(-1)) were administered topically to the skin in a single spot at monthly intervals. Quantitative fecal examinations were performed on days 0 (before treatment), 30, and 60. In the selamectin-treated cats, fecal ascarid egg counts were reduced by 99.6 to 100% on day 30, and by 99.9 to 100% on day 60. Fecal hookworm egg counts were reduced by 98.3% on day 30, and by 100% on day 60 in the selamectin-treated cats. The positive-control products achieved reductions in egg counts of 96.5 to 100% (ascarids) and 98.9 to 99.9% (hookworms). These studies have shown that monthly topical administration of selamectin is safe and highly effective in the treatment of naturally acquired ascarid and hookworm infections in cats.     

Efficacy of selamectin in the treatment of naturally acquired cheyletiellosis in cats

The purpose of this study was to evaluate the efficacy of a topical formulation of selamectin in the treatment of cheyletiellosis in cats. Fifteen adult domestic cats from the same household with naturally occurring Cheyletiella sp. infestation were enrolled in the study. On each cat, 45 mg of selamectin was applied on days 0, 30, and 60. No other treatment or environmental decontamination was performed during the trial. On days 0, 30, 60, and 120, all cats were examined, epidermal debris was collected over the dorsal area of the body with flea combs for microscopic examination, and fecal flotations were done. Clinical signs had subsided by day 60 in all 15 cats and no signs of recurrence were apparent on follow-up 1 year later. All epidermal and fecal samples were negative by day 60. No adverse reactions were observed. Under the conditions of our study, topical selamectin was a practical and well-tolerated means of treatment for cheyletiellosis in cats.